Track Group, Inc. TRCK
0.43 USD -0.01 (-2.27%)
Regular-session close
0.43 Day range 0.43
0.17 52-week range 0.81
- YTD
- +43.33%
- 1 year
- +59.26%
News
247wallst.com 2 Newer Monthly Paycheck ETFs vs. a Veteran: Does a Short Track Record Matter? A monthly check looks reliable until you ask which markets it has actually survived. Two young income ETFs and a 2003 veteran reveal what a payment history hides, and the answer may change how…
fool.com Dario Amodei Predicted at Davos in January 2025 That AI Could Surpass Humans “at Almost Everything” Within Two to Three Years. With Anthropic Now Filing for a $1.4 Trillion IPO, Is That Timeline Still on Track? Anthropic CEO Dario Amodei expects AI to become better than humans at most tasks, and soon. Per the AI benchmarks that exist, large language models are indeed becoming far more capable with each new…
marketbeat.com Solid Biosciences Eyes FDA Fast-Track Path for Duchenne Gene Therapy, Potential 2027 Filing Solid Biosciences NASDAQ: SLDB plans to meet with the U.S. Food and Drug Administration before the end of 2026 to discuss a potential accelerated approval pathway for its Duchenne muscular dystrophy…
globenewswire.com Teamshares Reports 3Q 2026 Results; Remains On-Track to Meet 2026 Outlook NEW YORK, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Teamshares (Nasdaq:TMS, the “Company”), a tech-enabled acquiror of high-quality SMEs, announced its financial results for 3Q26 and other business updates.…
globenewswire.com Creative Realities Reports Fiscal 2026 Third Quarter Results Revenue $26.2 Million, on Track for Record-Setting Year, Strong Outlook for 2027 Revenue $26.2 Million, on Track for Record-Setting Year, Strong Outlook for 2027
globenewswire.com Cardiff Oncology Receives FDA Fast Track Designation for Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer Designation covers onvansertib in combination with FOLFIRI/bevacizumab for adult patients with KRAS- or NRAS-mutated mCRC The designation is supported by clinical data from the ongoing randomized,…
seekingalpha.com i-80 Gold: Development Remains On Track, And The Stock Offers Great Value I rate i-80 Gold a strong buy: its $1.4B enterprise value compares with an estimated asset value of $5–8B. IAUX trades at 0.2–0.3 times estimated NPV using $4,000/oz gold and 5–10% discount rates,…
